- Home
- CASI vs BRNS Comparison
CASI vs BRNS Comparison
Compare CASI & BRNS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CASI
- BRNS
- Stock Information
- Founded
- CASI 1991
- BRNS 2016
- Country
- CASI China
- BRNS United Kingdom
- Employees
- CASI N/A
- BRNS N/A
- Industry
- CASI Biotechnology: Pharmaceutical Preparations
- BRNS Biotechnology: Pharmaceutical Preparations
- Sector
- CASI Health Care
- BRNS Health Care
- Exchange
- CASI Nasdaq
- BRNS Nasdaq
- Market Cap
- CASI 33.4M
- BRNS 28.2M
- IPO Year
- CASI 1996
- BRNS 2021
- Fundamental
- Price
- CASI $1.94
- BRNS $0.73
- Analyst Decision
- CASI Strong Buy
- BRNS Strong Buy
- Analyst Count
- CASI 1
- BRNS 2
- Target Price
- CASI $4.00
- BRNS $3.00
- AVG Volume (30 Days)
- CASI 13.6K
- BRNS 24.3K
- Earning Date
- CASI 05-13-2025
- BRNS 05-12-2025
- Dividend Yield
- CASI N/A
- BRNS N/A
- EPS Growth
- CASI N/A
- BRNS N/A
- EPS
- CASI N/A
- BRNS N/A
- Revenue
- CASI $28,537,000.00
- BRNS $14,969,000.00
- Revenue This Year
- CASI $66.12
- BRNS N/A
- Revenue Next Year
- CASI $51.37
- BRNS N/A
- P/E Ratio
- CASI N/A
- BRNS N/A
- Revenue Growth
- CASI N/A
- BRNS 1766.46
- 52 Week Low
- CASI $1.88
- BRNS $0.64
- 52 Week High
- CASI $7.67
- BRNS $2.77
- Technical
- Relative Strength Index (RSI)
- CASI 41.12
- BRNS 37.21
- Support Level
- CASI $1.91
- BRNS $0.68
- Resistance Level
- CASI $2.14
- BRNS $0.75
- Average True Range (ATR)
- CASI 0.20
- BRNS 0.08
- MACD
- CASI -0.01
- BRNS -0.00
- Stochastic Oscillator
- CASI 11.11
- BRNS 25.00
About CASI CASI Pharmaceuticals Inc.
CASI Pharmaceuticals Inc is a biopharmaceutical company that focuses on commercializing therapeutics and pharmaceutical products. The products include injections for patients who are suffering from leukemias and lymphomas. The EVOMELA injection is used as a conditioning treatment before autologous stem cell transplant for patients with multiple myeloma. The company products include CID-103, CNCT19, EVOMELA, MARQIBO, ZEVALIN, ENMD-2076 and others. The majority of the revenue is generated from the product sales of EVOMELA.
About BRNS Barinthus Biotherapeutics plc
Barinthus Biotherapeutics PLC is a clinical-stage biopharmaceutical company developing novel T-cell immunotherapeutics that guide the immune system to overcome chronic infectious diseases, autoimmunity, and cancer. The company operates as one segment, the research and development of immunotherapies and vaccines.